Multiple drugsQTc interval prolongation following off-label use: 5 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1908卷 / 1期

关键词：

D O I：

10.1007/s40278-022-16136-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：408 / 408

相关论文

共 50 条

[41] Multiple drugsIntestinal disorders following off-label use: 10 case reports
Reactions Weekly, 2022, 1932 (1) : 413 - 413
[42] Multiple drugsLack of efficacy following off-label use: 2 case reports
Reactions Weekly, 2021, 1872 (1) : 351 - 351
[43] Multiple drugsDelirium following off-label use and sedation: 10 case reports
Reactions Weekly, 2020, 1834 (1) : 176 - 177
[44] Multiple drugsLack of efficacy following off-label use: 3 case reports
Reactions Weekly, 2021, 1872 (1) : 352 - 352
[45] BevacizumabVarious toxicities following off-label use of bevacizumab: 5 case reports
Reactions Weekly, 2023, 1981 (1) : 90 - 90
[46] Bevacizumab/thalidomideVarious toxicities following off-label use: 5 case reports
Reactions Weekly, 2019, 1745 (1) : 78 - 78
[47] VenetoclaxTumour lysis syndrome following off-label use: 5 case reports
Reactions Weekly, 2020, 1786 (1) : 160 - 160
[48] ValproateSomnolence and lack of efficacy following off-label use: 5 case reports
Reactions Weekly, 2022, 1903 (1) : 362 - 362
[49] Hydroxychloroquine/lopinavir/ritonavirVomiting and QTc-interval prolongation following off-label therapy: 2 case reports
Reactions Weekly, 2021, 1858 (1) : 186 - 186
[50] Antibacterials/antiviralsQTc-interval prolongation and cardiac arrest following off-label therapy: 3 case reports
Reactions Weekly, 2021, 1840 (1) : 29 - 29

← 1 2 3 4 5 →